The management of invasive aspergillosis in patients with hematological malignancies remains controversial. A major problem is how to manage patients who had invasive aspergillosis during remission induction and consolidation therapy and then undergo SCT. Indeed in these patients the mortality rate related to invasive aspergillosis recurrence remains unacceptably high. We report two cases of patients who underwent remission induction for AML, developed invasive aspergillosis during antifungal prophylaxis with itraconazole, failed amphotericin B deoxycholate and liposomal amphotericin B treatment, were successfully treated with voriconazole and eventually underwent SCT with voriconazole prophylaxis without reactivation of invasive aspergillosis.
Invasive aspergillosis (IA) is an important cause of morbidity in patients with AML, being reported in a proportion of patients ranging from 5 to 29%. 1, 2 Despite the availability of new diagnostic procedures potentially able to allow early treatment, 3, 4 the mortality rate remains unacceptably high (50-70%). 2, [5] [6] Patients who survive the acute phase are usually successfully managed, due to antifungal treatment and bone marrow recovery. However, the causative agent may remain in the infected tissues and can reactivate following further courses of chemotherapy. 7 Although no large scale prospective study has ever been performed, there is some evidence that intravenous amphotericin B deoxycholate (D AmB) may be effective as secondary prophylaxis in SCT recipients. 8 have also suggested the possible efficacy of oral itraconazole (ITR) and liposomal amphotericin B (L AmB) for this indication. [9] [10] [11] In any case, even with prophylaxis, the relapse rate remains very high (33%), with a mortality rate among relapsed patients of 88%. 12 Therefore, there is a clear need for new strategies for patients undergoing SCT who have a history of IA. Voriconazole (VOR) is a new triazole derivative with potent, broad spectrum activity against the fungi responsible for opportunistic infections in immunocompromised patients. 13 The clinical efficacy, safety and tolerance of VOR have been recently confirmed in two large clinical trials in patients with IA.
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Patients and methods
Patient 1
In July 2000, a 44-year-old male with M4 AML received induction therapy with hydroxyurea, daunorubicin (DNR), etoposide (VP16) and cytarabine (Ara-C). Throughout therapy, he received antifungal prophylaxis with ITR oral solution (300 mg once daily) and was monitored with twice weekly serum ELISA tests for galactomannan (GAL) (BioRad Laboratories, Marnes La Coquette, France) and weekly chest computer tomographic (CT) scans for the early detection of IA. On 10 July 2000, since the GAL test had been positive in two consecutive samples, ITR was replaced with D AmB (1 mg/kg/day for 21 days, followed by L AmB 5 mg/kg/day for renal intolerance). Pulmonary CT scans were sequentially performed: the first was negative despite the positive GAL test, but the second revealed a right apical subpleuric nodule, that subsequently increased in size and then cavitated. Fine needle lung biopsy under CT guidance was performed and culture grew Aspergillus species, confirming the diagnosis. The patient did not achieve remission and remained on L AmB, with partial clinical response, until September 2000. At this time, during salvage anti-leukemic therapy with DNR, high dose Ara-C, and VP16, he had relapsing fever and a new lesion in the right pulmonary apex was detected ( Figure 1 ). L AmB was discontinued for clinical evidence of failure and VOR was started, first intravenously (6 mg/kg twice daily on day 1, then 4 mg/kg twice daily thereafter) and then orally (150 mg twice daily). In October 2000, while in partial remission, he underwent related HLA-identical BMT after conditioning with TBI 333 cGy once daily on days 1 to 3 (total dose 999 cGy) and cyclophosphamide (CTX) 60 mg/kg once daily i.v. on days 6 and 7 (total dose 120 mg/kg). GVHD prophylaxis consisted of cyclosporin A and methotrexate. The overall clinical course was uneventful with regard to infectious complications. VOR was administered for a total of 45 days and discontinued at the beginning of November 2000. At this point, the pulmonary CT scan was negative for any new lesions, with only one residual micronodule at the right apex ( 
Patient 2
In September 2000, a 57-year-old male with M2 AML received remission induction therapy with the same regimen as described above. He was given the same antifungal prophylaxis and entered the same program of sequential GAL and CT scan monitoring of IA. On 26 September 2000 he started empirical antifungal therapy (first D AmB at 1 mg/kg/day, and then L AmB at 5 mg/kg/day) for persistent fever not responding to broad-spectrum antibiotics. Despite this treatment, on 27 September he suddenly presented with severe chest pain and hemoptisis. A chest CT scan showed bilateral nodular lesions (that eventually underwent cavitation) and, on the same day, the GAL ELISA turned out to be positive. A fine needle lung biopsy was attempted but failed for technical reasons. The patient showed partial response to L AmB, with defervescence but no improvement in, and even slight enlargement of the pulmonary lesions (Figure 3 ). For this reason, on 24 October L AmB was replaced with VOR (i.v. and then orally) at standard dosage, with clear improvement of the pulmonary lesions. Following complete leukemia remission (November 2000), the patient underwent consolidation therapy with ARA-C, DNR and filgrastim, with successful harvest of PBSC. He was then autografted in January 2001 after conditioning with busulfan (4 mg/kg p.o. in divided doses daily for 4 days to a total dose 16 mg/kg) and CTX (60 mg/kg once daily i.v. on days 5 and 6 for a total dose of 120 mg/kg). Since the CT scan still revealed bilateral cavitating lesions, VOR was continued until 13 February, first intravenously and then orally. Throughout prophylaxis, the patient did not experience any major infectious complication, the GAL ELISA assays remained negative and the chest CT scan did not reveal any new lesions (Figure 4) . The patient is alive and free of both leukemia and IA 1 year after PBSCT.
Discussion
Patients with a history of IA appear to be at high risk of reactivation when undergoing further chemotherapy. This is probably due to the fact that fungal organisms remain viable in these lesions. 16 Whether or not the risk of relapse depends on the persistence of lesions is a matter of controversy. According to Martino et al, 16 the risk is lower in the presence of a complete radiological response, while for Offner et al, 12 patients may relapse even in the absence of residual lesions. What is universally agreed is that a history of IA is not an absolute contraindication to further chemotherapy and SCT. 10, [17] [18] Ideally, patients needing further treatment for leukemia should undergo surgical excision of the pulmonary lesions, but this is often impossible due to the impending risk of leukemia relapse or the presence of multiple, bilateral lesions. In any case, even surgical excision does not guarantee complete cure, since aspergillosis is usually a multifocal disease, at least at microscopic level. 12 Therefore, even if this indication has never been proven in large-scale clinical trials, secondary antifungal prophylaxis (or pre-emptive therapy) remains the only possible option in these patients. The drug of choice seems to be AmB (in any formulation), but ITR (alone or in combination) has also been used. [8] [9] [10] [11] 17, [19] [20] [21] The efficacy and safety of VOR in acute IA had been recently assessed in two large prospective studies. In a non-comparative, phase II, multicenter study of 116 patients with IA, Denning et al 14 found a response rate of 58% in patients with hematologic disorders and 26% in allogeneic SCT recipients. In a phase III, randomized clinical trial of VOR vs D AmB (both followed other licensed antifungal therapies) the EORTC and MSG study groups found a better 12-week response rate (53% vs 32%) and a better survival (71% vs 58%) in patients treated with VOR. 15 The present report suggests that VOR may be effective not only as therapy for IA, but also as secondary prophylaxis or pre-emptive therapy and provides the rationale for implementing randomized clinical trials for this indication. Both our patients had proven or probable IA 22 and were at high risk of relapse. In light of the long duration of VOR administration and the investigational nature of the indication, both patients were genotyped for defects in CYP2C19 on the basis of the polymerase chain reactionbased restriction endonuclease cleavage analysis. 23 Both patients were shown to be extensive VOR metabolizers.
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Indeed, in both cases VOR was well tolerated, with no visual hallucinations and only mild and transient WHO grade II hepatotoxicity in patient 1. This report confirms that IA occurring during the management of AML is not a contraindication to intensive chemotherapy and allogeneic or autologous SCT. If strict diagnostic monitoring is applied and antifungal treatment is promptly initiated, patients can survive the acute phase. Then, if an effective and well-tolerated antifungal treatment is administered pre-emptively for a prolonged period of time, relapse can be successfully prevented.
